Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with poor therapeutic response.
• Overexpression of enhancer of zeste homolog 2 (EZH2) is implicated in PDAC pathogenesis, malignancy, and treatment resistance.
• EZH2 contributes to immune evasion and an immunosuppressive tumor microenvironment, hindering immunotherapy efficacy.

Purpose of the Study:

• To investigate the role of EZH2 in PDAC progression and therapeutic resistance.
• To explore the potential of targeting EZH2 as a therapeutic strategy for PDAC.
• To understand EZH2-mediated mechanisms contributing to treatment failure and immune evasion in PDAC.

Main Methods:

• Analysis of EZH2 expression levels in PDAC patient cohorts.
• Investigation of EZH2's role in gene regulation via polycomb repressive complex 2 (PRC2) activity.
• Evaluation of EZH2's impact on tumor suppressor and apoptosis-related genes.
• Assessment of EZH2's contribution to immune evasion and the tumor microenvironment.

Main Results:

• High EZH2 expression in PDAC correlates with advanced stage, lymph node metastasis, and poor prognosis.
• EZH2 promotes tumor aggressiveness by regulating cell cycle, proliferation, and differentiation genes.
• EZH2-mediated epigenetic silencing contributes to resistance against conventional therapies and immune checkpoint inhibitors.
• Current EZH2 inhibitors have shown limited clinical efficacy in PDAC.

Conclusions:

• EZH2 is a critical driver of PDAC malignancy, therapeutic resistance, and immune evasion.
• Targeting EZH2 presents a potential therapeutic avenue for PDAC, but novel strategies are required.
• Further research into EZH2-mediated mechanisms is essential for developing effective PDAC treatments.